What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review

Rheumatology International

Volumn 36, Issue 4, 2016, Pages 483-487

  Erer, Burak ^a   Demirkaya, Erkan ^b   Ozen, Seza ^c   Kallinich, Tilmann ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute phase reactants; Amyloidosis; Diagnostic studies; Familial Mediterranean fever; Systematic review; Validation studies

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; SERUM AMYLOID A; BIOLOGICAL MARKER;

AMYLOIDOSIS; ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; COMPLICATION; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR;

ACUTE-PHASE PROTEINS; AMYLOIDOSIS; BIOMARKERS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84952021949     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3413-z     Document Type: Article

References (20)

1. Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43(2):227–253
2. Akar S, Yuksel F, Tunca M, Soysal O, Solmaz D, Gerdan V et al (2012) Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine 91(3):131–136
3. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D et al (2007) Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56(5):1706–1712
4. Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H et al (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology 53(4):741–745
5. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 84(1):1–11
6. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005
7. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M et al (2013) Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 43(3):387–391
8. Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119(2):e474–e483
9. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34(5):755–768
10. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S et al (2009) In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 206(5):1029–1036
11. Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112
12. Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D (2010) Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 69(4):677–682
13. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79–81
14. Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheum 21(4):509–514
15. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750
16. Yalcinkaya F, Cakar N, Acar B, Tutar E, Guriz H, Elhan AH et al (2007) The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. Rheumatol İnt 27(6):517–522
17. Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351(9103):659–664
18. Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M et al (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188
19. Yildirim K, Uzkeser H, Keles M, Karatay S, Kiziltunc A, Kaya MD et al (2012) Relationship between serum interleukin-1beta levels and acute phase response proteins in patients with familial Mediterranean fever. Biochemia Medica. 22(1):109–113
20. Tunca M (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415